Nature Communications · 2024 · 21 citations · 27 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Cell InfiltrationImmune Checkpoint InhibitorsImmuno-oncology BiomarkersTumor Immune MicroenvironmentCheckpoint Inhibitor CombinationsCombination Checkpoint TherapyImmune Cell DensityImmune Checkpoint BiomarkersImmune Checkpoint Blockade CombinationsImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor BiomarkersImmune Checkpoint Inhibitor Response
Abstract Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC), which may depend on tumor microenvironment (TME) characteristics. However, the relationship between the TME, usually characterized by immune cell density, and response to ICI is unclear. Here, we quantify the TME immune cell densities and spatial relationships (SRs) of 24 baseline UC samples, obtained before pre-operative combination ICI treatment, using multiplex immunofluorescence. We describe SRs by approximating the first nearest-neighbor distance distribution with a Weibull distribution and evaluate the association between TME metrics and ipilimumab+nivolumab response. Immune cell density does not discriminate between response groups. However, the Weibull SR metrics of CD8 + T cells or macrophages to their closest cancer cell positively associate with response. CD8 + T cells close to B cells are characteristic of non-response. We validate our SR response associations in a combination ICI cohort of head and neck tumors. Our data confirm that SRs, in contrast to density metrics, are strong biomarkers of response to pre-operative combination ICIs.
27
Fitting Linear Mixed-Effects Models Using <b>lme4</b>
Douglas M. Bates, Martin Mächler, Benjamin M. Bolker et al. · Journal of Statistical Software · 2015 · 85.6K citations · Full text
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations
Life Sciences, Immunology, Oncology +16
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles, Se Hoon Park, Éric Voog et al. · New England Journal of Medicine · 2020 · 1.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Thomas Powles, Ignacio Durán, Michiel S. van der Heijden et al. · The Lancet · 2017 · 1.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +12